Zobrazeno 1 - 10
of 325
pro vyhledávání: '"Nicholas J Ashton"'
Autor:
Joseph Mugisha, Nicholas J Ashton, Claire J Steves, Racheal Alinaitwe, Josephine Prynn, Tunde Peto, Beatrice Kimono, Martin Prince
Publikováno v:
Wellcome Open Research, Vol 9 (2024)
Background The prevalence of dementia in low- and middle-income countries is increasing, yet epidemiological data from African populations remain scarce. Crucial risk factors differ in Africa from more intensively studied global areas, including a hi
Externí odkaz:
https://doaj.org/article/db673c4e30424ea195c4fc5f0fc0715e
Autor:
Gemma Salvadó, Rik Ossenkoppele, Nicholas J Ashton, Thomas G Beach, Geidy E Serrano, Eric M Reiman, Henrik Zetterberg, Niklas Mattsson‐Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 5, Pp n/a-n/a (2023)
Abstract Several promising plasma biomarkers for Alzheimer's disease have been recently developed, but their neuropathological correlates have not yet been fully determined. To investigate and compare independent associations between multiple plasma
Externí odkaz:
https://doaj.org/article/adc3e327988745318065d88c1f77d745
Autor:
Juan Lantero‐Rodriguez, Anniina Snellman, Andrea L Benedet, Marta Milà‐Alomà, Elena Camporesi, Laia Montoliu‐Gaya, Nicholas J Ashton, Agathe Vrillon, Thomas K Karikari, Juan Domingo Gispert, Gemma Salvadó, Mahnaz Shekari, Christina E Toomey, Tammaryn L Lashley, Henrik Zetterberg, Marc Suárez‐Calvet, Gunnar Brinkmalm, Pedro Rosa Neto, Kaj Blennow
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 12, Pp n/a-n/a (2021)
Abstract Alzheimer’s disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p‐tau) species such as p‐tau217 and p‐tau231 provide accurate detection of early pathological changes, other biomarkers capable of st
Externí odkaz:
https://doaj.org/article/a5fc24b2a60148e8ada0fe84e8c1fdbc
Autor:
Marc Suárez‐Calvet, Thomas K Karikari, Nicholas J Ashton, Juan Lantero Rodríguez, Marta Milà‐Alomà, Juan Domingo Gispert, Gemma Salvadó, Carolina Minguillon, Karine Fauria, Mahnaz Shekari, Oriol Grau‐Rivera, Eider M Arenaza‐Urquijo, Aleix Sala‐Vila, Gonzalo Sánchez‐Benavides, José Maria González‐de‐Echávarri, Gwendlyn Kollmorgen, Erik Stoops, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, José Luis Molinuevo, for the ALFA Study
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 12, Pp n/a-n/a (2020)
Abstract In Alzheimer’s disease (AD), tau phosphorylation in the brain and its subsequent release into cerebrospinal fluid (CSF) and blood is a dynamic process that changes during disease evolution. The main aim of our study was to characterize the
Externí odkaz:
https://doaj.org/article/fa10944cadf0424c84138b7b13f06a8e
Autor:
Elena Camporesi, Johanna Nilsson, Ann Brinkmalm, Bruno Becker, Nicholas J Ashton, Kaj Blennow, Henrik Zetterberg
Publikováno v:
Biomarker Insights, Vol 15 (2020)
Synapses are the site for brain communication where information is transmitted between neurons and stored for memory formation. Synaptic degeneration is a global and early pathogenic event in neurodegenerative disorders with reduced levels of pre- an
Externí odkaz:
https://doaj.org/article/d071481bfb604cd8902ac917ba97b557
Autor:
Marco Antônio De Bastiani, Bruna Bellaver, Wagner S. Brum, Debora G. Souza, Pamela C.L. Ferreira, Andreia S. Rocha, Guilherme Povala, João Pedro Ferrari-Souza, Andrea L. Benedet, Nicholas J. Ashton, Thomas K. Karikari, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto, Tharick A. Pascoal, Eduardo R. Zimmer
Publikováno v:
Brain, Behavior, and Immunity. 110:175-184
Autor:
Daniele Altomare, Sara Stampacchia, Federica Ribaldi, Szymon Tomczyk, Claire Chevalier, Géraldine Poulain, Saina Asadi, Bianca Bancila, Moira Marizzoni, Marta Martins, Aurelien Lathuiliere, Max Scheffler, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Ilse Kern, Miguel Frias, Valentina Garibotto, Giovanni B Frisoni
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 94:420-427
BackgroundThe key Alzheimer’s disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid Aβ42and p-tau181), or poorly s
Autor:
Ying Meng, Maged Goubran, Jennifer S Rabin, Melissa McSweeney, Julie Ottoy, Christopher B Pople, Yuexi Huang, Alexandra Storace, Miracle Ozzoude, Allison Bethune, Benjamin Lam, Walter Swardfager, Chinthaka Heyn, Agessandro Abrahao, Benjamin Davidson, Clement Hamani, Isabelle Aubert, Henrik Zetterberg, Nicholas J Ashton, Thomas K Karikari, Kaj Blennow, Sandra E Black, Kullervo Hynynen, Nir Lipsman
Publikováno v:
Brain. 146:865-872
The blood–brain barrier (BBB) protects the brain but is also an important obstacle for the effective delivery of therapeutics in Alzheimer’s disease and other neurodegenerative disorders. Transcranial magnetic resonance-guided focused ultrasound
Autor:
Joel, Simrén, Haley, Weninger, Wagner S, Brum, Shilla, Khalil, Andréa L, Benedet, Kaj, Blennow, Henrik, Zetterberg, Nicholas J, Ashton
Publikováno v:
Alzheimer's & Dementia. 18:1988-1992
Recent evidence has shown that the marker of reactive astrogliosis, glial fibrillary acidic protein (GFAP), has a stronger relationship with cerebral amyloid beta (Aβ) pathology in blood than in cerebrospinal fluid (CSF). This study investigates if
Autor:
Shorena Janelidze, Divya Bali, Nicholas J Ashton, Nicolas R Barthélemy, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Yingxin He, Anna Orduña Dolado, Gallen Triana-Baltzer, Michael J Pontecorvo, Henrik Zetterberg, Hartmuth Kolb, Manu Vandijck, Kaj Blennow, Randall J Bateman, Oskar Hansson
Publikováno v:
Brain. 146:1592-1601
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amy